Medipost had already earned global recognition as a leader in stem cell therapeutics through the development of CARTISTEM® and the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) product. As the company expanded into the U.S. market, they needed a digital presence that could introduce their scientific leadership to researchers, clinicians, partners, and investors across the American biotechnology landscape.
Working in collaboration with Longview Strategies, Stark Raving’s team led the design and development of Medipost’s new U.S. website. Building on the company’s existing brand identity, we created a modern digital experience that communicated Medipost’s mission, scientific leadership, and regenerative medicine expertise while making highly technical information more accessible to a broad professional audience.
From visual design through front-end development, every aspect of the website was crafted to position Medipost as an emerging force within the U.S. biotechnology sector. Contemporary layouts, refined motion design, and streamlined navigation helped communicate innovation and precision while guiding visitors through the company’s therapies, clinical pipeline, research focus, and expanding presence in the United States with clarity and confidence.
The final result was a polished and credible U.S. web presence that aligned Medipost’s international reputation with its long-term ambitions in the American regenerative medicine market. More than a corporate website, the platform became an important part of the company’s broader market entry strategy, helping to establish visibility, strengthen stakeholder trust, and support future clinical and commercial growth in the United States.
